News Alembic Pharmaceuticals Limited

Equities

APLLTD

INE901L01018

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 03:06:04 2026-02-09 EST			5-day change	1st Jan Change
794.70 ^INR	-0.37%		+1.62%	-6.08%

03:16am	India's Zydus Life posts surprise profit rise on strong North American sales	RE
02-06	Alembic Pharmaceuticals Gets Final Nod for Parkinson Treatment Tablets; Shares Down 3%	MT

03:16am	India's Zydus Life posts surprise profit rise on strong North American sales	RE
02-06	Alembic Pharmaceuticals Gets Final Nod for Parkinson Treatment Tablets; Shares Down 3%	MT
02-05	Alembic Pharmaceuticals Limited, Q3 2026 Earnings Call, Feb 05, 2026
02-05	Alembic Pharmaceuticals' Consolidated Profit Declines in Fiscal Q3	MT
02-05	Alembic Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
02-05	Alembic Pharma Q3 consol profit 1.33 billion rupees	RE
02-05	Drugmaker Alembic Pharma posts earnings dip on Indian labour code changes	RE
01-31	Alembic Pharmaceuticals Limited Announces Superannuation of Resident Director Ashok Pandya, Effective January 31, 2026	CI
01-27	Alembic Pharmaceuticals receives USFDA final approval for difluprednate emulsion	RE
01-27	Alembic Pharmaceuticals Ltd announces USFDA final approval for difluprednate ophthalmic emulsion, 0.05%	RE
01-27	Alembic Pharmaceuticals Limited Receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%	CI
01-12	Alembic Pharmaceuticals Limited Receives USFDA Tentative Approval for Bosutinib Tablets, 400 Mg	CI
01-12	Alembic Pharmaceuticals Gets Tentative Nod from US FDA for Bosutinib Tablets	MT
01-12	Alembic Pharmaceuticals receives USFDA tentative approval for bosutinib tablets, 400 mg	RE
12-18	Alembic Pharmaceuticals gets USFDA final approval for travoprost ophthalmic solution	RE
12-18	Alembic Pharmaceuticals Limited Announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution	CI
12-11	Alembic Gets US FDA's Final Nod for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension	MT
12-11	Alembic Pharmaceuticals Limited Receives Final Approval from the Us Food & Drug Administration for Its Abbreviated New Drug Application Loteprednol Etabonate and Tobramycin Ophthalmic Suspension	CI
12-01	Alembic Pharmaceuticals Limited Announces Resignation of Prashant Khandelwal, Head-International Business Formulations, Effective December 1, 2025	CI
11-14	Alembic Pharmaceuticals Limited Receives USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg	CI
11-13	Alembic Pharmaceuticals Gets US FDA Final Nod for Dexlansoprazole Delayed-Release Capsules	MT
11-13	Alembic Pharmaceuticals receives USFDA approval for dexlansoprazole capsules	RE
11-13	Alembic Pharmaceuticals Limited Receives USFDA Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Dexlansoprazole Delayed-Release Capsules, 30 Mg	CI
11-07	Indian Equities End Flat on Friday as Late Buying Offsets Early Weakness in IT, FMCG	MT
11-07	Alembic Pharmaceuticals receives USFDA final approval for sumatriptan injection USP	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Alembic Pharmaceuticals Limited

Equities

APLLTD

INE901L01018

Pharmaceuticals

Filters